These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6201179)

  • 41. Sulphydryls, ascorbate and oxygen as modifiers of the toxicity and metabolism of misonidazole in vitro.
    Taylor YC; Rauth AM
    Br J Cancer; 1980 Jun; 41(6):892-900. PubMed ID: 7426314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of hypoxia on oxidative and reductive pathways of omeprazole metabolism by the isolated perfused rat liver.
    Webster LK; Jones DB; Mihaly GW; Morgan DJ; Smallwood RA
    Biochem Pharmacol; 1985 Apr; 34(8):1239-45. PubMed ID: 3994745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Binding of 14C-misonidazole to hypoxic cells in V79 spheroids.
    Franko AJ; Chapman JD
    Br J Cancer; 1982 May; 45(5):694-9. PubMed ID: 7082555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolism and radiosensitization of 4,5-dimethylmisonidazole, a ring-substituted analog of misonidazole.
    Born JL; Smith BR; Harper N; Koch CJ
    Biochem Pharmacol; 1992 Mar; 43(6):1337-44. PubMed ID: 1562284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reductive fragmentation of 2-nitroimidazoles in the presence of nitroreductases--glyoxal formation from misonidazole.
    Raleigh JA; Liu SF
    Biochem Pharmacol; 1983 Apr; 32(8):1444-6. PubMed ID: 6687998
    [No Abstract]   [Full Text] [Related]  

  • 46. In situ drug delivery.
    Levin VA; Wright DC; Landahl HD; Patlak CS; Csejtey J
    Br J Cancer Suppl; 1980 Apr; 4():74-8. PubMed ID: 6932949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Accumulation Mechanism of 2-Nitroimidazole-based Hypoxia Imaging Probes Revealed by Imaging Mass Spectrometry].
    Shimizu Y
    Yakugaku Zasshi; 2018; 138(11):1345-1352. PubMed ID: 30381642
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benznidazole: nitroreduction and inhibition of cytochrome P-450 in chemosensitization of tumour response to cytotoxic drugs.
    Workman P; Walton MI; Lee FY
    Biochem Pharmacol; 1986 Jan; 35(1):117-9. PubMed ID: 3940522
    [No Abstract]   [Full Text] [Related]  

  • 49. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver.
    Arteel GE; Thurman RG; Yates JM; Raleigh JA
    Br J Cancer; 1995 Oct; 72(4):889-95. PubMed ID: 7547236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circadian changes in the elimination of misonidazole in mouse.
    Labat C; Malmary MF; Casanovas AM; Patau JP; Oustrin J
    Res Commun Chem Pathol Pharmacol; 1983 Nov; 42(2):331-4. PubMed ID: 6658193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypoxia mediated binding of misonidazole in non-malignant tissue.
    Rasey JS; Hoffman JM; Spence AM; Krohn KA
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1255-8. PubMed ID: 3744948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glutathione peroxidase activity and release of glutathione from oxygen-deficient perfused rat heart.
    Guarnieri C; Flamigni F; Rossoni-Caldarera C
    Biochem Biophys Res Commun; 1979 Jul; 89(2):678-84. PubMed ID: 486188
    [No Abstract]   [Full Text] [Related]  

  • 53. Misonidazole binding in murine liver tissue: a marker for cellular hypoxia in vivo.
    Maxwell AP; MacManus MP; Gardiner TA
    Gastroenterology; 1989 Nov; 97(5):1300-3. PubMed ID: 2792663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Causes of apparent low levels of misonidazole in human tumours.
    Ash DV; Smith MR
    Clin Radiol; 1980 Mar; 31(2):233-7. PubMed ID: 7363558
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phenytoin sodium-induced alterations in the pharmacokinetics of misonidazole in the dog.
    White RA; Workman P
    Cancer Treat Rep; 1980; 64(2-3):360-1. PubMed ID: 7190871
    [No Abstract]   [Full Text] [Related]  

  • 56. Glutathione disulfide formation occurring during hypoxia and reoxygenation of rat lung.
    Jenkinson SG; Marcum RF; Pickard JS; Orzechowski Z; Lawrence RA; Jordan JM
    J Lab Clin Med; 1988 Oct; 112(4):471-80. PubMed ID: 3171355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biliary and faecal excretion of misonidazole in man.
    Ash DV; Smith MR
    Br J Radiol; 1979 Oct; 52(622):846-8. PubMed ID: 509037
    [No Abstract]   [Full Text] [Related]  

  • 58. No significant effect of metoclopramide on misonidazole elimination in man.
    Williams KM; Begg EJ; Wade DN; O'Shea K
    Br J Clin Pharmacol; 1983 Mar; 15(3):390-2. PubMed ID: 6849772
    [No Abstract]   [Full Text] [Related]  

  • 59. The pharmacokinetics of misonidazole in the dog.
    White RA; Workman P; Freedman LS; Owen LN; Bleehen NM
    Eur J Cancer (1965); 1979 Oct; 15(10):1233-42. PubMed ID: 520395
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.
    Akel G; Canal P; Mockey E; Vandevoorde E; Laurent F; Soula G
    J Pharmacol; 1983; 14(1):67-77. PubMed ID: 6834852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.